๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Relapsed Pediatric ALL

Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis NCT07220252Phase 2, Phase 36 sites๐Ÿ“ Salt Lake City๐Ÿ“ Gdansk๐Ÿ“ Poznan TG Therapeutics, Inc. ยท Tests: Ublituximab, Placebo, Placebo, Fingolimod CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL NCT06559189Phase 11 site๐Ÿ“ Aurora University of Colorado, Denver ยท Tests: CD19x22 CAR T Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors NCT02508038Phase 11 site๐Ÿ“ Madison University of Wisconsin, Madison ยท Tests: TCRฮฑฮฒ+/CD19+ depleted Haploidentical HSCT, Zoledronate A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents NCT05334823Phase 216 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Chongqing Chongqing Precision Biotech Co., Ltd ยท Tests: pCAR-19B cells A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias NCT06397027Phase 11 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Ziftomenib, Venetoclax, Azacitidine A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma NCT05533775Phase 1, Phase 230 sites๐Ÿ“ Birmingham๐Ÿ“ Oakland๐Ÿ“ Oakland Hoffmann-La Roche ยท Tests: Obinutuzumab, Glofitamab, Rituximab, Ifosfamide, Carboplatin Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia NCT06581081NA1 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: Senl_B19 autologous CAR-T (S1904) treatment A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) NCT06561074Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Decitabine, Venetoclax, Calaspargase pegol-mknl Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas NCT07222735Phase 11 site๐Ÿ“ Memphis St. Jude Children's Research Hospital ยท Tests: Fludarabine, Cyclophosphamide, B7-H3-CAR T Cells, Radiation Therapy Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation NCT06316960Phase 212 sites๐Ÿ“ Hefei๐Ÿ“ Hefei๐Ÿ“ Guangzhou Children's Hospital of Soochow University ยท Tests: Avapritinib, Azacitidine Injection, Decitabine Injection, Idarubicin Hydrochloride, Cytarabine Niclosamide in Pediatric Patients With Relapsed and Refractory AML NCT05188170Phase 11 site๐Ÿ“ Palo Alto Stanford University ยท Tests: Niclosamide A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) NCT05667506Phase 1, Phase 29 sites๐Ÿ“ Hefei๐Ÿ“ Chongqing๐Ÿ“ Guangzhou Juventas Cell Therapy Ltd. ยท Tests: single dose of CNCT19 Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse NCT07871864Phase 377 sites๐Ÿ“ Aarhus๐Ÿ“ Aarhus๐Ÿ“ Copenhagen Gustave Roussy, Cancer Campus, Grand Paris ยท Tests: Experimental group : Cabometyx ยฎ 40mg/m2/day (Max: 60mg/day) , Treatment schedule : Daily**, day 1-28 during 4 weeks (iโ€ฆ A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) NCT06173518Phase 114 sites๐Ÿ“ Los Angeles๐Ÿ“ Palo Alto๐Ÿ“ Aurora Autolus Limited ยท Tests: AUTO1 A Phase I Dose Finding Study of MB-CART2219.1 NCT07108868Phase 12 sites๐Ÿ“ Tรผbingen๐Ÿ“ Tรผbingen University Hospital Tuebingen ยท Tests: CAR-T cells targeting CD19 and CD22 Determining the Mechanisms of Loss of CAR T Cell Persistence NCT05809284n/a3 sites๐Ÿ“ London๐Ÿ“ London๐Ÿ“ Manchester University College, London Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Becotatug Vedotin UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL NCT04544592Phase 1, Phase 21 site๐Ÿ“ Aurora University of Colorado, Denver ยท Tests: CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma NCT07375563Phase 31 site๐Ÿ“ Moscow Federal Research Institute of Pediatric Hematology, Oncologโ€ฆ ยท Tests: Dinutuximab beta, temozolomide, irinotecan, autologous NK cell, irinotecan, temozolomide, dinutuximab beta, NK-cell proโ€ฆ Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia NCT05512169n/a2 sites๐Ÿ“ New Delhi๐Ÿ“ Puducherry University of Geneva, Switzerland An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older NCT06666491Phase 35 sites๐Ÿ“ Ahmedabad๐Ÿ“ Bikaner๐Ÿ“ Kolkata GlaxoSmithKline ยท Tests: Tafenoquine, Primaquine, Chloroquine Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma NCT06013618Phase 21 site๐Ÿ“ Guangzhou Sun Yat-Sen University Cancer Center ยท Tests: Naxitamab monotherapy, GM-CSF, Irinotecan, Temozolomide, Naxitamab in combination therapy HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies NCT05658640Phase 1, Phase 236 sites๐Ÿ“ Vienna๐Ÿ“ Ghent๐Ÿ“ Copenhagen Princess Maxima Center for Pediatric Oncology ยท Tests: Trametinib, Dexamethasone, Cyclophosphamide, Cytarabine, Intrathecal chemotherapy A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) NCT06191978Phase 11 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: ASTX727, Venetoclax HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies NCT05751044Phase 1, Phase 233 sites๐Ÿ“ Vienna๐Ÿ“ Ghent๐Ÿ“ Copenhagen Princess Maxima Center for Pediatric Oncology ยท Tests: Dasatinib, Venetoclax, Dexamethasone, Cyclophosphamide, Cytarabine Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation NCT07256210Phase 21 site๐Ÿ“ Moscow Federal Research Institute of Pediatric Hematology, Oncologโ€ฆ ยท Tests: Donor-derived Natural Killer Cell Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia NCT05869279Phase 1, Phase 21 site๐Ÿ“ Bergamo Fondazione Matilde Tettamanti Menotti De Marchi Onlus ยท Tests: CARCIK-CD19 Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia NCT05366218Phase 1, Phase 211 sites๐Ÿ“ Freiburg im Breisgau๐Ÿ“ Tรผbingen๐Ÿ“ Ulm University Hospital Tuebingen ยท Tests: Tafasitamab Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors NCT05608148Phase 11 site๐Ÿ“ Fukuoka Kyushu University ยท Tests: Biological, Biological, Biological, Biological Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL NCT06635330Phase 1, Phase 21 site๐Ÿ“ Tehran Kara Yakhteh Tajhiz Azma Company ยท Tests: anti-CD19 CAR T cell therapy
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy